highly accelerated region 1AGenealiases: HAR1F · LINC00064 · NCRNA00064
Q-omics provides the consensus-scored HAR1A profile across patient tissues and cancer cell-line models. HAR1A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HAR1A is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, HAR1A RNA expression shows 13,893 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where HAR1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HAR1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HAR1A survival associations across molecular data types. HAR1A RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HAR1A RNA expression–survival associations across cancer types. High HAR1A expression shows unfavorable associations in KIRC, LAML and UVM, but favorable associations in LGG, ACC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HAR1A RNA expression.
This table summarizes HAR1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HAR1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HAR1A shows lower tumor expression in BLCA, LUSC and UCEC and higher tumor expression in HNSC, KIRC and COAD. The BLCA box plot shows higher HAR1A RNA expression in normal versus tumor tissue (log2 FC = −0.663, t-test p < 0.001).
This table shows molecular features associated with HAR1A in patient tissues and cancer cell lines. In patient samples, HAR1A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
